Pregnancy-associated plasma protein A (PAPP-A) is a biomarker routinely used in screening for Down syndrome in the fi rst trimester of pregnancy. It is also present in very small amounts in men and non-pregnant women. PAPP-A is a key regulator of local insulin-like growth factor (IGF) bioavailability -IGFs are essential for normal body size during fetal development, but they are associated with aging and agerelated diseases. Measurement of circulating PAPP-A can provide valuable information not only in pregnant women (chromosomal anomalies and adverse pregnancy outcomes) but also in patients with coronary artery disease (contribution to diagnosis, prognostic value) and in patients with kidney diseases. PAPP-A is associated with renal function and proteinuria, is increased mainly in dialysis patients and decreases after kidney transplantation. It is an independent mortality predictor of hemodialysis patients and indicator of adverse outcome of transplanted patients. PAPP-A levels can be infl uenced by various chemicals and drugs, among them mainly heparin. Various assays for PAPP-A exist and the type of assay used in a study should be considered. This article reviews the data summarizing basic information about PAPP-A with a particular focus on the signifi cance of PAPP-A in renal diseases.
Introduction
Pregnancy-associated plasma protein A (PAPP-A) is a biomarker routinely used in screening for Down syndrome in the fi rst trimester of pregnancy. Despite its name " pregnancy protein " it is also present in very small amounts in non-pregnant individuals, both men and women and is implicated in various processes, such as wound healing, bone remodeling or atherosclerosis. Measurement of circulating PAPP-A can provide valuable information not only in pregnant women but also in patients with coronary artery disease and in patients with kidney diseases.
In this review we would like to summarize basic information about PAPP-A and focus on the signifi cance of PAPP-A in renal diseases -what was demonstrated in experimental, genetic, laboratory, clinical and pharmacological studies.
History of PAPP-A in laboratory medicine
PAPP-A was originally isolated in 1974 as one of four placental proteins circulating in high concentrations in pregnant women (1) . In 1990 it was shown that low maternal serum level of PAPP-A in the fi rst trimester of pregnancy is characteristic for Down syndrome fetus development (2) , and measurement of PAPP-A was introduced in the fi rst trimester screening of chromosomal anomalies (3) . There is increasing evidence that low levels of PAPP-A in the fi rst trimester are associated with adverse outcomes, such as preterm delivery, intrauterine growth retardation, preeclampsia, and stillbirth (4) . In the third trimester in preeclamptic pregnancies, PAPP-A is increased (5) .
In 2001, PAPP-A was found in eroded and ruptured atherosclerotic plaques and its serum levels were increased in patients with acute coronary syndromes (6) . Many studies regarding the usefulness of PAPP-A screening in cardiology were performed. PAPP-A was demonstrated as a marker of the presence and extent of atherosclerosis in coronary and peripheral arterial diseases, a marker of outcome in stable atherosclerotic disease and in some studies as a marker of worst prognosis in acute coronary syndrome and as a marker that might help in the diagnosis of acute coronary syndrome [reviewed in (7) ]. Controversy exists due to different assays used in the studies.
In 2003, we fi rst described elevation of PAPP-A in patients with end-stage renal disease treated with hemodialysis (8) , and subsequently its relationship to renal function (9) and its possible prognostic role in long-term hemodialysis patients (10) . Elevation of PAPP-A measured by a different method with lower reference range was also confi rmed by Coskun et al. (11) .
PAPP-A has been studied in a variety of diseases, e.g., in diabetes mellitus, allergy and obesity. In diabetic patients, no difference in PAPP-A levels in DM1 or DM2 and healthy subjects was found (12) and another group did not fi nd its usefulness as a biomarker of carotid atherosclerosis in type 2 diabetics (13) . Conversely, PAPP-A was associated with increased mortality in type 1 diabetic patients with nephropathy but only in unadjusted analysis; after adjustment for traditional risk factors the prognostic value of PAPP-A was no longer signifi cant (14) . PAPP-A was signifi cantly elevated in allergic rhinitis (15) and in asthma and correlated with asthma severity (16) . In children there was no difference between obese and lean subjects but a correlation with other cardiovascular risk factors was found (17) .
Biology of PAPP-A: gene structure and function
The gene for PAPP-A in humans is located on chromosome 9q33.1 (18) , spans over 200 kb of DNA, and contains 22 exons with a length from 72 to 1063 nucleotides separated by 21 introns of various length (19) . PAPP-A is synthesized as a 1627-residue precursor preproprotein with a 22-residue putative signal peptide and a propeptide of 58 residues, so that the mature protein then contains 1547 amino acids. PreproPAPP-A mRNA has an unusually long 5 ′ untranslated region that contains several ORF (20) . The PAPP-A amino acid sequence is, to a high extent, identical with other mammals which suggests its essential function. Additionally, PAPP-A was also found in non-mammalian vertebrates but not in invertebrates (21) .
The PAPP-A protein (PAPP-A monomer) containing 1547 amino acids has pI 5.4 and molecular weight 200 kDa. It is composed of fi ve domains: the N-terminal laminin like domain, the metzincin proteolytic domain which is responsible for insulin-like growth factor binding proteins (IGFBPs) cleavage, a central domain of unknown identity, a domain defi ned by fi ve complement control protein modules which is responsible for binding to the cell surface and a C-terminal domain (21) . PAPP-A exists as a homodimer of 400 kDa which is proteolytically active and as a proteolytically inactive PAPP-A/pro major basic protein (MBP) heterotetrameric complex of 500 kDa (21) . The complexed PAPP-A is the major form of PAPP-A in pregnancy (22) while the free (uncomplexed) form is the only relevant form in acute coronary syndromes (23) .
PAPP-A is expressed by various cell types -fi broblasts, vascular smooth muscle cells, osteoblasts, ovarian granulose cells, trophoblasts cells, and to a lesser extent by endothelial cells. It is not expressed by macrophages (21) . PAPP-A is secreted and then binds to cell surfaces in an autocrine/ paracrine manner (24, 25) .
PAPP-A (pappalysin-1, E.C. 3.4.24.79) is a zinc binding protease which together with PAPP-A2 (pappalysin-2) and ulilysin belongs to pappalysins, one of fi ve subfamilies of the metzincin superfamily of metalloproteinases. PAPP-A2 shares 45 % homology with PAPP-A and unlike PAPP-A it is unable to bind to cells. Ulilysin was found in archebacteria Methanosarcina acetotivorans (26) . PAPP-A is responsible for proteolytic cleavage of IGFs, mainly IGFBP-4 but also -2 and -5 and so acts as a positive regulator of IGF availability (27 -29) . PAPP-A is a key regulator of IGF-II bioavailability during early embryogenesis and plays a similar role regulating IGF-I bioavailability postnatally (21) . PAPP-A like other metzincins has the ability to cleave itself resulting in fragments of 150 kDa and 50 kDa (30) .
PAPP-A is present in healthy individuals in very low concentration (6, 8) . During normal pregnancy it rises linearly and after labor it disappears from circulation with a half-life of 3 -4 days (31) . In acute coronary syndromes it is increased early after the onset of symptoms (fi rst ca 7 h) (32) .
Experimental studies
PAPP-A is a key regulator of local IGF bioavailability. IGFs are essential for normal body size during fetal development, however, IGFs are associated with aging and age-related diseases. That is why loss of PAPP-A or inhibition of PAPP-A activity should have negative effects early in life and beneficial effects later in life (33) .
PAPP-A knockout mice are smaller in body size but have signifi cantly increased life span compared with wild-type littermates. Incidence of neoplastic disease was not significantly different in wild-type and PAPP-A knockout mice; however, it did occur in older aged PAPP-A knockout mice compared to wild-type mice. Additionally, PAPP-A knockout mice were less likely to show degenerative changes of aging. Nephropathy was more evident and more severe in wild-type than in PAPP-A knockout mice. The kidney, an organ with the highest PAPP-A expression levels in wild-type mice, had the most marked changes in gene expression in PAPP-A knockout mice (34) . Swindel et al. (35) demonstrated higher expression of IGFBPs-1 and 2, decreased expression of IGFBPs-3 and 5 and no change of IGFBP-4 expression in PAPP-A knockout mice compared to wild-type mice.
In contrast, transgenic mice with over expression of PAPP-A in arterial smooth muscle show accelerated atherosclerotic lesion development (36) .
Genetic studies
In the database of polymorphisms of the National Center for Biotechnology Information the following polymorphisms are registered (July 27, 2011): 44 polymorphisms in exon sequences, 37 polymorphisms in non-translated regions and more than 2000 polymorphisms in intron sequences. In exons, 13 synonymous polymorphisms (silent mutations), 26 non-synonymous polymorphisms and two deletions are found (Table 1 ) .
Only three papers studying PAPP-A polymorphisms have been published to date. The fi rst found a relationship between Asn1007Ser  rs10983107  11  Ile1056Val  rs111984106  12  Gly1111Gly  rs79136957  14  Asp1253Asp  rs112369830  Ser1224Tyr  rs7020782  15  Arg1315His  rs116551272  Pro1317Leu  rs60642076  16  Cys1362Cys  rs2296069  Pro1351Ala  rs55679739  Val1383Met  rs55901693  17  Lys1401Gln  rs35947124  18  Leu1451Pro  rs117752286  19  Val1534Val  rs3827668  22  Asp1601Asp  rs10759836  His1612Gln  rs35109458  Asp1605Asp  rs62575393   Table 2 Summarization of main fi ndings regarding PAPP-A in patients with kidney disease. Ser1224Tyr polymorphism (rs 7020782, exon 14) and increased risk of repeated abortions (37) . The second study was performed in patients with acute myocardial infarction and demonstrated polymorphism rs13290387 (c/g) on intron 6 as an independent risk factor of acute myocardial infarction (38) . The third study was performed by our group -we were searching for three polymorphisms Arg654Lys, Ala678Pro and Thr686Ala in exon 5, and two polymorphisms Phe802Leu, and Ser827Ser/Leu in exon 7, and for new mutations in exon 5 and 7 of the PAPP-A gene in a group of over 200 subjects; however, we did not fi nd any divergence from wild-type form for these polymorphisms in any of the studied subjects, which lead us to the hypothesis that these polymorphisms are not associated with the Caucasian population (39) . No study regarding PAPP-A gene polymorphisms is available in patients with kidney diseases.
PAPP-A assays
Several PAPP-A assays, in house or commercial, with different specifi cities exist and are used for measurement of PAPP-A. That is why reference ranges and values in studied groups in various studies sometimes differ. PAPP-A assays usually measure total PAPP-A (i.e., PAPP-A/proMBP and free PAPP-A). Concentration of free PAPP-A is the difference between total PAPP-A and complexed PAPP-A, i.e., difference between two assays. Direct free PAPP-A determination is to date not available.
As already mentioned, PAPP-A in pregnancy is predominantly complexed with proMBP. This complex is also present at very low concentration in non-pregnant individuals. In hemodialysis patients, both total and free PAPP-A concentration is increased (40) . In patients with acute coronary syndromes, the PAPP-A increase is given by the increase of free (uncomplexed) PAPP-A and this increase might not always be detected by classical tests used in pregnancy (23, 41, 42) . Additionally, PAPP-A can be degraded into smaller fragments of 150 kDa and 50 kDa and it is questionable whether these fragments are also detected by the assays and whether they are relevant for diagnostics. Without a doubt, standardization of the assay would be essential.
Studies in nephrology unlike cardiology are relatively rare. In our studies as well as in the study of Etter et al. (43) Immunoanalyzer (Innotrac Diagnostics). Total PAPP-A concentration in hemodialysis patients was 9.0 (6.9 -11.9) mIU/L and concentration of free PAPP-A was 5.2 (4.2 -7.0) mIU/L (median and IQR) (40) .
Another point that should be addressed is timing of PAPP-A collection since it can be infl uenced by previous application of heparin (see below) (40) . Of note, in vitro addition of heparin to blood does not infl uence PAPP-A concentration.
Clinical and laboratory studies in patients with kidney diseases
In 2003, we fi rst described elevation of PAPP-A in patients with end-stage renal disease treated with hemodialysis (8) . PAPP-A levels are three-fold higher than in healthy controls, however 100 -1000-fold lower than in the fi rst trimester of pregnancy. Elevation of PAPP-A in hemodialysis patients measured by a different method giving lower values was confi rmed Coskun et al. (11) .
PAPP-A is associated with renal function (9) as well as with proteinuria and negatively with albumin (46) . PAPP-A is signifi cantly elevated mainly in patients with end-stage renal disease with lower levels in patients treated with peritoneal dialysis than in patients treated with hemodialysis (9) . PAPP-A is detectable also in spent peritoneal dialysate but these concentrations are not related to serum levels. However, PAPP-A in dialysate signifi cantly correlates with protein losses to the dialysate (r = 0.66, p < 0.05) and with CA 125 as a marker of peritoneal damage (r = 0.56, p < 0.05) (our unpublished observation). In hemodialysis patients PAPP-A correlates signifi cantly with another pregnancy protein, placental growth factor (PlGF), matrix metalloproteinases MMP-2 and 9, molecules linked to its action IGF-1 and IGFBP-4 and cardiac markers troponin (cTnI) and brain natriuretic peptide (BNP) and creatinine. We did not fi nd an association with albumin, cholesterol, CRP, orosomucoid, and retinol (44) . Concerning its changes during dialysis, PAPP-A signifi cantly increases at the beginning of the procedure -hemodialysis or hemodiafi ltration -without a difference between these two procedures, probably due to heparin application and then decreases until the end of the procedure (47) . Similar behavior of PAPP-A during hemodialysis with diacetatecellulosic, polyamid (48) and polysulfon membranes was observed (49) .
PAPP-A decreases after kidney transplantation, and correlates with graft function and with histological changes in 3-month protocol biopsy (intragraft intersticial infl ammation and intima thickening) (50) . However, PAPP-A is higher in transplanted patients than in patients with chronic kidney disease with the same glomerular fi ltration rate (50) . It is signifi cantly correlated with infl ammatory markers C-reactive protein, interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α ) (45) .
In 2004, we described in our preliminary study of 40 hemodialysis patients higher PAPP-A levels in patients who died during the 20-months follow-up compared to survivors suggesting a possible prognostic role of PAPP-A (10) . Our hypothesis was confi rmed in our defi nitive study in 261 long-term hemodialysis patients who were followed for 5 years -PAPP-A was an independent predictor of overall mortality and mortality due to infection in hemodialysis patients (44) . Similarly, PAPP-A was shown as an independent short-time predictor of mortality in a smaller study (170 patients) (43) . Additionally, several studies dedicated to PAPP-A in renal transplant recipients -its pre-transplant serum concentration serves also as a predictor of post-transplant cardiovascular events and chronic allograft nephropathy (45) and could be a risk factor of delayed graft function (51) . Similarly, as in patients with acute coronary syndrome, coronary artery disease and peripheral artery disease where PAPP-A was identifi ed as an independent marker of cardiovascular events and death (7) , elevated PAPP-A in hemodialysis patients could be a surrogate marker refl ecting systemic atherosclerosis and adverse outcome ( Table 2) .
Pharmacological infl uence of PAPP-A expression and circulating PAPP-A levels
PAPP-A expression is stimulated by TNF-α and interleukin 1 beta (IL1-β ) (52 -54) and this cytokine induced expression can be inhibited by antioxidants N-acetyl cysteine (53) or polyphenol resveratrol (54) . Resveratrol is found in the skin of grapes and in red wine which might contribute to the explanation of the French paradox of benefi cial effect of consumption of red wine on reduced cardiovascular risk. Antioxidant vitamin E (400 mg daily for 5 weeks) in long-term hemodialysis patients had no effect on PAPP-A levels (55) .
The effect of statins on PAPP-A levels was tested in small clinical studies. Atorvastatin in high-dose (80 mg) significantly decreased PAPP-A after 1-month treatment while a low dose of atorvastatin did not have this effect (56) . Another study did not demonstrate any effect of 20 mg atorvastatin daily on PAPP-A levels (57) .
PAPP-A levels are signifi cantly increased by heparin administration (unfractionated heparin as well as low molecular weight heparin enoxaparin) but are not infl uenced by another anticoagulant, bivalirudin (40, 58) . Total PAPP-A increased up to 25-fold within 5 min after heparin administration and the increase was given by free PAPP-A. Free PAPP-A was then cleared rapidly, 85 % in the fi rst rapid phase (half-life 13.1 min) and the remaining 15 % in the second slower phase (half-life 96.6 min) (58) . Repeated heparin bolus induced a new PAPP-A release. Subcutaneous low molecular weight heparin led to lower and slower free PAPP-A elevation. An increase of total PAPP-A at the beginning of hemodialysis (PAPP-A measured 15 min after start of dialysis and after heparin application) was also observed by our group (47, 48) . We discussed the possible effects of heparin (47) and its role in PAPP-A redistribution as binding of PAPP-A to heparinSepharose was used for PAPP-A purifi cation from pregnant plasma in 1983 (59) . As heparin is widely used in patients with acute coronary syndromes and hemodialysis patients and expert evaluation of heparin administration in patients was published only in 2009 (40) , this might have infl uenced the results of some previous studies and explain some discrepancies in study results. In our studies, blood for basal PAPP-A was collected before heparin administration and patients with permanent catheters were excluded to avoid possible infl uence on the results.
Sodium ferric gluconate is another drug increasing PAPP-A levels. We have observed a two-fold increase in PAPP-A 1 h after administration of 62.5 mg sodium ferric gluconate which is indispensable for proper function of erythropoietin in hemodialysis patients, and its subsequent decrease (49) ( Table 3 ) .
Summary
In summary, PAPP-A is a protein with many functions within as well as outside pregnancy. Measurement of circulating PAPP-A can bring valuable information in pregnant women and also in patients with coronary artery disease and in patients with kidney diseases. PAPP-A is associated with renal function and proteinuria, is increased mainly in dialysis patients and decreases after kidney transplantation. It is an independent mortality predictor of hemodialysis patients and indicator of adverse outcome of transplanted patients. However, various assays for PAPP-A exist and the type of assay used should be considered. Further studies with higher numbers of patients and standardization of PAPP-A assay are required to show the usefulness of PAPP-A measurement and enable its possible introduction into routine clinical practice in other indications than fi rst trimester pregnancy screening.
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